EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of a 14‐day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study

Shu-Yan Zeng, Juan Wang, Jing Liu, Min-Juan Lin, Bo-Shen Lin, Yu-Ming Ding, Qing-Zhou Kong, Wen-Lin Zhang, Miao Duan, Zhong-Xue Han, Yue-Yue Li iD, Xiu-Li Zuo iD und 1 weitere

Journal of Gastroenterology and Hepatology · 2023

DOI: 10.1111/jgh.16348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Shu-Yan Zeng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Taishan Scholars Program of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim After three treatment failures, Helicobacter pylori infection is deemed refractory as antibiotic treatment options become significantly limited. This study evaluated the efficacy and safety of a 14‐day modified concomitant therapy for managing refractory H. pylori infection.

Methods

Patients who had failed to respond to three or more rounds of H. pylori therapies were recruited for this study. They received a 14‐day modified concomitant therapy, including esomeprazole 40 mg, amoxicillin 1000 mg, and furazolidone 100 mg twice daily and tetracycline 500 mg four times daily. Demographic data, adverse events, and patient compliance were recorded. The presence of H. pylori was reevaluated 6 weeks following treatment. Eradication rate was assessed as the primary outcome.

Results

Overall, 59 participants received the 14‐day modified concomitant therapy. In the intention‐to‐treat and per‐protocol analyses, the eradication rate was 84.7% (50/59) and 89.3% (50/56), respectively. H. pylori was successfully isolated from 75.0% (12/16) of patients. The resistance rate of H. pylori to metronidazole, levofloxacin, and clarithromycin was 91.7% (11/12), 58.3% (7/12), and 50.0% (6/12), respectively. Resistance to amoxicillin, furazolidone, or tetracycline was not observed. The frequency of adverse events was 35.6% (21/59), with no serious adverse events reported.

Conclusion

The 14‐day modified concomitant therapy appears to be appropriate for refractory H. pylori infection and is particularly promising for the Chinese population. A randomized controlled trial is warranted to verify its efficacy, especially in the current environment of increasing antibiotic resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriHumansPilot ProjectsFurazolidoneDrug Therapy, CombinationAnti-Bacterial AgentsAmoxicillinMetronidazoleClarithromycinTreatment Outcome

Stichwörter der Autor:innen

FurazolidoneHelicobacter pyloriPilot studyRescue treatmentTetracycline

Substanzen

FurazolidoneAnti-Bacterial AgentsAmoxicillinMetronidazoleClarithromycin

Autor:innen und Institutionen

  • Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Hospital Development Center of Qingdao Municipal Health Commission, Qingdao, Shandong, China.

ORCID-Profile: Yue-Yue Li, Xiu-Li Zuo, Yan-Qing Li

Förderung

  • National Natural Science Foundation of China
  • Taishan Scholars Program of Shandong Province

Zitieren

APA

Zeng, S. Y., Wang, J., Liu, J., Lin, M. J., Lin, B. S., Ding, Y. M., Kong, Q. Z., Zhang, W. L., Duan, M., Han, Z. X., Li, Y. Y., Zuo, X. L., & Li, Y. Q. (2023). Efficacy and safety of a 14‐day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16348

Vancouver

Zeng SY, Wang J, Liu J, Lin MJ, Lin BS, Ding YM, et al. Efficacy and safety of a 14‐day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16348

BibTeX
@article{Zeng2023,
  author = {Zeng, Shu-Yan and Wang, Juan and Liu, Jing and Lin, Min-Juan and Lin, Bo-Shen and Ding, Yu-Ming and Kong, Qing-Zhou and Zhang, Wen-Lin and Duan, Miao and Han, Zhong-Xue and Li, Yue-Yue and Zuo, Xiu-Li and Li, Yan-Qing},
  title = {Efficacy and safety of a 14‐day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2023},
  doi = {10.1111/jgh.16348}
}
Kostenlos starten →